Brokerages Expect Gilead Sciences, Inc. (GILD) Will Post Quarterly Sales of $5.37 Billion
Brokerages expect Gilead Sciences, Inc. (NASDAQ:GILD) to announce $5.37 billion in sales for the current fiscal quarter, Zacks Investment Research reports. Seven analysts have made estimates for Gilead Sciences’ earnings, with estimates ranging from $5.05 billion to $5.64 billion. Gilead Sciences reported sales of $6.51 billion during the same quarter last year, which indicates a negative year over year growth rate of 17.5%. The firm is expected to issue its next quarterly earnings report on Tuesday, May 1st.
According to Zacks, analysts expect that Gilead Sciences will report full year sales of $5.37 billion for the current financial year, with estimates ranging from $20.31 billion to $21.63 billion. For the next financial year, analysts forecast that the business will report sales of $20.95 billion per share, with estimates ranging from $19.04 billion to $22.18 billion. Zacks’ sales averages are a mean average based on a survey of sell-side research firms that cover Gilead Sciences.
Gilead Sciences (NASDAQ:GILD) last released its earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.78 earnings per share for the quarter, beating analysts’ consensus estimates of $1.67 by $0.11. Gilead Sciences had a return on equity of 50.29% and a net margin of 17.73%. The company had revenue of $5.95 billion during the quarter, compared to analyst estimates of $5.71 billion. During the same quarter in the previous year, the company posted $2.70 EPS. Gilead Sciences’s revenue for the quarter was down 18.7% on a year-over-year basis.
Gilead Sciences (GILD) traded up $1.51 during midday trading on Wednesday, hitting $80.91. The stock had a trading volume of 5,630,000 shares, compared to its average volume of 9,940,000. Gilead Sciences has a 12 month low of $63.76 and a 12 month high of $89.54. The company has a market cap of $107,670.00, a price-to-earnings ratio of 10.54, a PEG ratio of -1.82 and a beta of 1.22. The company has a debt-to-equity ratio of 1.10, a quick ratio of 3.48 and a current ratio of 3.55.
The business also recently declared a quarterly dividend, which will be paid on Thursday, March 29th. Stockholders of record on Friday, March 16th will be given a $0.57 dividend. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.52. This represents a $2.28 dividend on an annualized basis and a dividend yield of 2.82%. The ex-dividend date is Thursday, March 15th. Gilead Sciences’s payout ratio is currently 27.08%.
In other news, Director Gayle E. Wilson sold 60,000 shares of the business’s stock in a transaction that occurred on Friday, February 9th. The stock was sold at an average price of $77.92, for a total value of $4,675,200.00. Following the sale, the director now directly owns 182,258 shares of the company’s stock, valued at approximately $14,201,543.36. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, EVP Gregg H. Alton sold 14,435 shares of the business’s stock in a transaction that occurred on Tuesday, February 20th. The stock was sold at an average price of $81.54, for a total value of $1,177,029.90. The disclosure for this sale can be found here. Over the last three months, insiders sold 432,768 shares of company stock worth $33,919,138. Insiders own 1.30% of the company’s stock.
Several institutional investors and hedge funds have recently modified their holdings of GILD. Welch Investments LLC bought a new position in Gilead Sciences in the 3rd quarter valued at approximately $108,000. Wealthcare Advisory Partners LLC bought a new position in Gilead Sciences in the 3rd quarter valued at approximately $133,000. Certified Advisory Corp bought a new position in Gilead Sciences in the 4th quarter valued at approximately $133,000. Horan Capital Advisors LLC. bought a new position in Gilead Sciences in the 3rd quarter valued at approximately $144,000. Finally, Migdal Insurance & Financial Holdings Ltd. bought a new position in Gilead Sciences in the 2nd quarter valued at approximately $147,000. 75.71% of the stock is currently owned by hedge funds and other institutional investors.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.